Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential
The DOI matches its Crossref record.
Abstract
Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the liver. Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be linked to the process because they preferentially activate c-Src in highly-metastatic cells. EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following ligand activation of the EGFR, but only in highly-metastatic cells. Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the SRC activation signature score was significantly associated with metastasis and primary tumor stage I-IV progression (Fig. 2g,h), in agreement with previous studies in CRC [37–40].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [39]
Citations
Cited by
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
“In A431 cells and in colon carcinoma cell lines, endogenous c-Src has constitutively elevated kinase activity, which is reduced to basal levels by the EGFR-specific kinase inhibitor AG1478 [146,147].”
BackgroundYeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Self-citationRole of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857
“First, Src can be activated by receptor tyrosine kinases such as EGFR and HGF receptor (Maa et al., 1995; Mao et al., 1997).”
BackgroundInfluentialSelf-citationSrc family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
The interplay between Src and integrins in normal and tumor biology
Playford, M. P., & Schaller, M. D. (2004) · Oncogene · doi:10.1038/sj.onc.1208080 · Cited by 523
“…in Src protein levels and/or altered protein stability, an increase in upstream receptor tyrosine kinase activity, or loss of key regulatory proteins (Maa et al., 1995; Mao et al., 1997; Egan et al., 1999; Hakak and Martin, 1999; Harris et al., 1999; Shimakage et al., 2000; Masaki et al., 2003).”
BackgroundActivating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Self-citationNewest findings on the oldest oncogene; how activated src does it
Frame, M. C. (2004) · Journal of Cell Science · doi:10.1242/jcs.01111 · Cited by 367
“An inhibitory mutant of N-WASP impairs podosome formation as well as v-Src-induced matrix degradation, indicating a probable link between control of actin assembly and the formation of structures that mediate Src-induced matrix remodelling (Mizutani et al., 2002).”
BackgroundSrc-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling
Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M. A., Brunton, V. G., & Frame, M. C. (2002) · Nature Cell Biology · doi:10.1038/ncb829 · Cited by 362
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344
“It has been reported that in highly metastatic human colon cancer cell lines, both MET and EGFR activate SRC (36).”
BackgroundHiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274
“Elevated Src kinase activity has also been observed in highly metastatic cells when compared to poorly metastatic cells and in tissues from cancer patients [34].”
BackgroundThe C2 Domain of PKCδ Is a Phosphotyrosine Binding Domain
Benes, C. H., Wu, N., Elia, A. E. H., Dharia, T., Cantley, L. C., & Soltoff, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.019 · Cited by 246
c-Src, Receptor Tyrosine Kinases, and Human Cancer
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60774-5 · Cited by 243
Malignant melanoma: modern black plague and genetic black box
Chin, L., Merlino, G., & DePinho, R. A. (1998) · Genes & Development · doi:10.1101/gad.12.22.3467 · Cited by 194
“…et al. 1998); PLC-g has been implicated in cell chemotaxis (Derman et al. 1996); association with Src correlates with a highly metastatic state (Mao et al. 1997); and full induction of the urokinase proteolysis network (Jeffers et al. 1996) involves both Ras and PI3-K (Besser et al. 1997).”
BackgroundEpidermal growth factor receptor
Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P. J., Ward, C. W., & Burgess, A. W. (2003) · The EGF Receptor Family · doi:10.1016/b978-012160281-9/50004-9 · Cited by 181
“In A431 cells and in colon carcinoma cell lines, endogenous c-Src has constitutively elevated kinase activity, which is reduced to basal levels by the EGFR-specific kinase inhibitor AG1478 [146,147].”
BackgroundGrowth Factors in Inflammatory Bowel Disease
Beck, P. L., & Podolsky, D. K. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199902000-00007 · Cited by 180
Pichot, C. S., Hartig, S. M., Xia, L., Arvanitis, C., Monisvais, D., Lee, F. Y., Frost, J. A., & Corey, S. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605101 · Cited by 173
“Elevated Src activity has been shown to increase growth rate (Mao et al, 1997) and metastatic potential, while inhibiting cell –cell adhesion (Hamaguchi et al, 1993) in human cancers.”
BackgroundCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Khan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., Raza, S. S., & Shahab Uddin, M. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112142 · Cited by 174
Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D., & Moore, C. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00405-6 · Cited by 148
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“This interaction of SFKs with RTKs can result in enhanced or synergistic SFK activation and has been demonstrated in tumor types, most notably in HNSCC, NSCLC and CRC (Fu et al., 2008; Koppikar et al., 2008; Mao et al., 1997; Zhang et al., 2007).”
BackgroundInfluentialAdhesion signaling by a novel mitotic substrate of src kinases
Bhatt, A. S., Erdjument‐Bromage, H., Tempst, P., Craik, C. S., & Moasser, M. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208582 · Cited by 135
“In a subset of these tumors, this is due to mutational activation of src (Mao et al., 1997; Irby and Fujita, 1999; Sugimura et al., 2000).”
BackgroundSerrels, A., Macpherson, I. R. J., Evans, T. R. J., Lee, F. Y., Clark, E. A., Sansom, O. J., Ashton, G. H., Frame, M. C., & Brunton, V. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0382 · Cited by 124
“The involvement of Src in growth factor–induced mitogenesis has been known for many years (4), and the interaction of Src with growth factor receptors in tumor cells (35, 36) suggests that Src may cooperate with other signaling pathways to drive proliferation of certain tumor types.”
BackgroundHsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
Koga, F., Xu, W., Karpova, T. S., McNally, J. G., Baron, R., & Neckers, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604705103 · Cited by 118
Activated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia
Karni, R., Dor, Y., Keshet, E., Meyuhas, O., & Levitzki, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206141200 · Cited by 116
Koppikar, P., Choi, S.-H., Egloff, A. M., Cai, Q., Suzuki, S., Freilino, M., Nozawa, H., Thomas, S. M., Gooding, W. E., Siegfried, J. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5226 · Cited by 115
Kazansky, A. V., Kabotyanski, E. B., Wyszomierski, S. L., Mancini, M. A., & Rosen, J. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22484 · Cited by 119
Adhesion-linked kinases in cancer; emphasis on Src, focal adhesion kinase and PI 3-kinase
Jones, R. J., Brunton, V., & Frame, M. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00153-2 · Cited by 130
“With regard to metastasis, endogenous Src expression is increased in secondary tumours compared with their primary counterparts in an animal model of colorectal cancer metastasis [34].”
BackgroundSrc Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., & Gray, N. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454126 · Cited by 107
“Other possible mechanisms include increased expression due to enhanced mRNA levels [55], defective proteasomal degradation [31, 33], down-regulation of negative regulatory proteins such as drs [56] as well as stimulation by growth factor receptors, above all ErbB2, EGF and c-Met [57].”
BackgroundActivity of the multikinase inhibitor dasatinib against ovarian cancer cells
Konecny, G. E., Glas, R., Dering, J., Manivong, K., Qi, J., Finn, R. S., Yang, G. R., Hong, K.-L., Ginther, C., Winterhoff, B. J. N., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605381 · Cited by 104
“…EGFR (Tice et al, 1999), HER2 (Muthuswamy et al, 1994), fibroblast growth factor receptor (Landgren et al, 1995), or hepatocyte growth factor (Mao et al, 1997) can result in Src activation, most likely by disrupting the intramolecular interactions that hold Src in a closed and inactive…”
BackgroundSrc as a potential therapeutic target in non-small-cell lung cancer
Giaccone, G., & Zucali, P. A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn048 · Cited by 99
“In addition, Src activity is higher in metastatic tissue compared with primary tumours and cells with limited metastatic potential [9].”
BackgroundEGFR signaling to p120-catenin through phosphorylation at Y228
Mariner, D. J., Davis, M. A., & Reynolds, A. B. (2004) · Journal of Cell Science · doi:10.1242/jcs.01001 · Cited by 107
“Moreover, it is well-established that EGFR activity stimulates Src and vice versa (Mao et al., 1997; Osherov and Levitzki, 1994; Oude Weernink et al., 1994) (reviewed by Frame, 2002).”
BackgroundAltered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis
Wei, L., Yu, Y., Zhang, X., & Yu, Q. (2004) · Oncogene · doi:10.1038/sj.onc.1208091 · Cited by 93
“Src activity is elevated in highly metastatic colon cancer cells when compared to poorly metastatic colon tumor cells (Mao et al., 1997).”
BackgroundInfluentialSrc inhibitors: drugs for the treatment of osteoporosis, cancer or both?
Šušva, M., Missbach, M., & Green, J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01567-4 · Cited by 95
Sen, A., O'Malley, K., Wang, Z., Raj, G. V., DeFranco, D. B., & Hammes, S. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134064 · Cited by 89
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
“The activated Src upregulates the expression of c-Met [15–17], while EGF promotes the interaction between human epidermal growth factor receptor 2 (HER2) and Src in the CRC cells [15].”
BackgroundJones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80
“Cells were visualised using a confocal microscope (model MRC600; BioRad Labs, Hercules, CA, USA).”
BackgroundMethodInfluentialc-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Belli, S., Esposito, D., Servetto, A., Pesapane, A., Formisano, L., & Bianco, R. (2020) · Cancers · doi:10.3390/cancers12061489 · Cited by 89
Functional implication of the interaction between EGF receptor and C-SRC
Leu, T., & Maa, M.-C. (2003) · Frontiers in bioscience · doi:10.2741/980 · Cited by 87
“Furthermore, significant increase in c-Src activity is observed in highly metastatic cells as compared to cells with poor metastatic potential (68).”
BackgroundMiyake, T., & Parsons, S. J. (2011) · Oncogene · doi:10.1038/onc.2011.332 · Cited by 81
“Since EGF stimulation induces c-Src binding to the EGFR and activation (Stover et al 1995) (Mao et al 1997), it is likely that in normal cells the binding of EGF ligand activates EGFR and c-Src (Ishizawar and Parsons 2004), which in turn enhances the association of EGFR with and activation and/or…”
BackgroundHornia, A., Lu, Z., Sukezane, T., Zhong, M., Joseph, T. W., Frankel, P., & Foster, D. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7672 · Cited by 76
“In this report, we describe the antagonistic effects of PKC a and d on both transformation and PLD activity in cells that overexpress the EGF receptor (EGFR cells); like c-Src, the EGF receptor is implicated in many human cancers (2, 27, 28).”
BackgroundTanaka, Y., Kobayashi, H., Suzuki, M., Kanayama, N., & Terao, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309131200 · Cited by 77
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
Herynk, M. H., Stoeltzing, O., Reinmuth, N., Parikh, N. U., Abounader, R., Laterra, J., Radinsky, R., Ellis, L. M., & Gallick, G. E. (2003) · PubMed · Cited by 71
E-cadherin mutations and cell motility: A genotype–phenotype correlation
Mateus, A. R., Simões‐Correia, J., Figueiredo, J., Heindl, S., Alves, C. C., Suriano, G., Luber, B., & Seruca, R. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.02.020 · Cited by 84
Sirvent, A., Bénistant, C., Pannequin, J., Veracini, L., Simon, V, Bourgaux, J.-F., Hollande, F., Cruzalegui, F., & Roche, S. (2010) · Oncogene · doi:10.1038/onc.2009.450 · Cited by 69
“These include growth factor receptors, via their association with SFK-SH2 (Mao et al., 1997) and tyrosine phosphatases that dephosphorylate pTyr529 (Liang et al., 2007; Zheng et al., 2008; Zhu et al., 2007).”
BackgroundDemers, M., Thibodeau, S., Noël, D., Fujita, N., Tsuruo, T., Gauthier, R., Arguin, M., & Vachon, P. H. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22131 · Cited by 69
“EGFR is frequently highly expressed and active (mainly through autocrine stimulation) in epithelial tumors, including colon cancers [Mao et al., 1997; Karnes et al., 1998; Danielsen and Maihle, 2002; Thomson et al., 2003; Henson and Gibson, 2006; Normanno et al., 2006].”
BackgroundResultDickinson, S. I., Zhang, H. Q., Yuan, Z. Q., Cheng, J. Q., Karl, R. C., Jove, R., & Coppola, D. (2003) · Human Pathology · doi:10.1053/s0046-8177(03)00354-x · Cited by 73
Self-citationSawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Active Src Elevates the Expression of β-Catenin by Enhancement of Cap-Dependent Translation
Karni, R., Gus, Y., Dor, Y., Meyuhas, O., & Levitzki, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.12.5031-5039.2005 · Cited by 73
“Activation of the proto-oncoprotein pp60 (c-Src) is the hallmark of many types of cancer, especially highly metastatic ones (12, 13, 22).”
BackgroundShore, S. K. (2003) · Frontiers in Bioscience · doi:10.2741/1138 · Cited by 65
“Stepwise increases in Src activity have been observed during pre-malignant ulcerative colitis, polyp formation, invasive tumors, and ultimately in metastatic lesions (21-32).”
BackgroundYoshida, T., Okamoto, I., Okamoto, W., Hatashita, E., Yamada, Y., Kuwata, K., Nishio, K., Fukuoka, M., Janne, P. A., & Nakagawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01368.x · Cited by 63
Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408550200 · Cited by 60
Zheng, X., Resnick, R. J., & Shalloway, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23321 · Cited by 60
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Sirvent, A., Bénistant, C., & Roche, S. (2012) · Europe PMC (PubMed Central) · Cited by 78
Src Inhibitors in Lung Cancer: Current Status and Future Directions
Rothschild, S. I., Gautschi, O. P., Haura, E. B., & Johnson, F. M. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.030 · Cited by 59
Lee, E., Jeon, M., Kim, B.-D., Kim, J.-H., Kwon, Y., Lee, H., Lee, Y. S., Yang, J.-H., & Kim, T. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.034 · Cited by 58
Risk of malignancy among patients with rheumatic conditions
Thomas, E., Brewster, D. H., Black, R. J., & Macfarlane, G. J. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001101)88:3<497::aid-ijc27>3.0.co;2-j · Cited by 332
Targeting Src signaling in metastatic bone disease
Araujo, J., & Logothetis, C. (2009) · International Journal of Cancer · doi:10.1002/ijc.23998 · Cited by 58
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
Hiscox, S., Morgan, L., Green, T., & Nicholson, R. I. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01297 · Cited by 57
Differing Src Signaling Levels Have Distinct Outcomes in Drosophila
Vidal, M., Warner, S., Read, R., & Cagan, R. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1376 · Cited by 57
“For example, Src synergizes with EGFR to direct oncogenic growth in fibroblasts (5).”
BackgroundNovel regulation and function of Src tyrosine kinase
Ma, Y. C., & Huang, X. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8438-2 · Cited by 58
Dong, Y., He, Y., de Boer, L., Stack, M. S., Lumley, J. W., Clements, J. A., & Hooper, J. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335448 · Cited by 62
Src, chemoresistance and epithelial to mesenchymal transition: are they related?
Shah, A. N., & Gallick, G. E. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801265d7 · Cited by 54
Feigin, M. E., & Muthuswamy, S. K. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.034 · Cited by 60
“In a panel of human colon cancer cell lines, ErbB1 and ErbB2-regulated Src activity was associated with highly metastatic cell populations [73], suggestive of a role for Src in the invasive phenotype.”
BackgroundSaeed, M. E. M., Jacob, S., Sandjo, L. P., Sugimoto, Y., Khalid, H. E., Opatz, T., Thines, E., & Efferth, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00267 · Cited by 57
“All cell lines were incubated in a humidified 5% CO2 atmosphere at 37◦C and passaged twice weekly.”
BackgroundMethodImproving the prognosis for patients with glioblastoma: the rationale for targeting Src
de Groot, J., & Milano, V. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9916-2 · Cited by 59
Menges, C. W., Chen, Y., Mossman, B. T., Chernoff, J., Yeung, A. T., & Testa, J. R. (2010) · Genes & Cancer · doi:10.1177/1947601910375273 · Cited by 57
“EGFR, MET and SFK can positively regulate one another and can signal downstream to the same pathways, including the PI3K-AKT-mTOR and MAPK signaling cascades.(25-27,40,41,46,48,65,68,69) EGFR and SRC have been shown to activate MET to allow serum-independent growth in human bladder carcinoma cells.”
BackgroundQian, Y., Baisden, J. M., Zot, H. G., Van Winkle, W. B., & Flynn, D. C. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4795 · Cited by 51
Growth factors in inflammatory bowel disease
Beck, P. L., & Podolsky, D. K. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780050108 · Cited by 51
Luo, F., Barrett, Y. C., Yang, Z., Camuso, A., McGlinchey, K., Wen, M.-L., Smykla, R. A., Fager, K., Wild, R., Palme, H., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0699-5 · Cited by 51
“activity than poorly metastatic cells; mutations in a critical carboxy-terminal tyrosine regulatory region of SRC lead to SRC activation and increased metastasis [11, 12].”
BackgroundMolecular targets and pathways involved in liver metastasis of colorectal cancer
Weidle, U. H., Birzele, F., & Krüger, A. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9732-3 · Cited by 53
Src inhibitors: genomics to therapeutics
Sawyer, T. K., Boyce, B. F., Dalgarno, D. C., & Iuliucci, J. D. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1327 · Cited by 50
“Elevated Src expression or activity has been correlated with tumour growth in specific cancers having ErbB2 or cMet receptors [2,36,37], by studies using Src-specific antisense DNA [48,49], and the recent identification of activating Src mutations in advanced human colon cancer [50].”
BackgroundRet-mediated mitogenesis requires Src kinase activity.
Melillo, R. M., Barone, M. V., Lupoli, G., Cirafici, A. M., Carlomagno, F., Visconti, R., Matoskova, B., Fiore, P. P. D., Vecchio, G., Fusco, A., et al. (1999) · PubMed · Cited by 58
The molecular rationale of Src inhibition in colorectal carcinomas
Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47
“The b-arrestin/c-src interaction was proved to be critical for the regulation of CRC cell migration in vitro and metastatic potential in vivo.76 Given the above findings, c-src is a strong mediator between EGFR and other receptors’ signaling and owns the capacity of transactivating EGFR.”
BackgroundInfluentialAlford, V. M., Kamath, A., Ren, X., Kumar, K., Gan, Q., Awwa, M., Tong, M., Seeliger, M. A., Cao, J. P., Ojima, I., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00758 · Cited by 48
Su, B., Gao, L., Meng, F., Guo, L.-W., Rothschild, J. G., & Gelman, I. H. (2012) · Oncogene · doi:10.1038/onc.2012.218 · Cited by 47
“Although there are rare cases of breast and colon cancers expressing Src containing activating mutations akin to the so-called “viral Src signature” (66,67), Src likely drives oncogenic progression by virtue of being overexpressed or activated by upstream growth factor receptors (68,69).”
The Src-Induced Mesenchymal State in Late-Stage Colon Cancer Cells
Avizienyte, E., Brunton, V. G., Fincham, V. J., & Frame, M. C. (2005) · Cells Tissues Organs · doi:10.1159/000084511 · Cited by 45
“Conclusion The role of elevated Src tyrosine kinase activity, and its mechanism of action in colon cancer cells are important because expression and activity of Src are elevated during progression to advanced stage disease [Mao et al., 1997; Jones et al., 2002].”
BackgroundKwon, O. S., An, S., Kim, E., Yu, J., Hong, K. Y., Lee, J. S., & Jang, S. K. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1117 · Cited by 45
Liu, Q., Sheng, Z., Cheng, C., Zheng, H., Lanuti, M. D., Liu, R., Wang, P., Shen, Y., & Xie, Z. (2021) · Advanced Science · doi:10.1002/advs.202102079 · Cited by 49
The v-Src SH3 Domain Facilitates a Cell Adhesion-independent Association with Focal Adhesion Kinase
Hauck, C. R., Hunter, T. R., & Schlaepfer, D. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009329200 · Cited by 46
Irby, R., Mao, W., Coppola, D., Jove, R., Gamero, A. M., Cuthbertson, D. D., Fujita, D. J., & Yeatman, T. J. (1997) · PubMed · Cited by 47
Self-citationBasis and Importance of SRC as a Target in Cancer
Levin, V. A. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_6 · Cited by 53
Song, J. J., Kim, J.-H., Sun, B. K., Alcala, M. A., Bartlett, D. L., & Lee, Y. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.10.007 · Cited by 43
Campbell, E., McDuff, E., Tatarov, O., Tovey, S., Brunton, V., Cooke, T., & Edwards, J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604768 · Cited by 50
“Tumour cell lines possessing elevated Src activity are often highly metastatic, displaying an increased capacity for migration and invasion in vitro (Mao et al, 1997; Jackson et al, 2000; Slack et al, 2001).”
Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients
Laghi, L., Bianchi, P., Orbetegli, O., Gennari, L., Roncalli, M., & Malesci, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1560 · Cited by 42
“…colorectal cancer (Ottenhoff-Kalff et al, 1992; Talamonti et al, 199 Thus, activated expression of c-Src, a cellular human proto-onco homologous to the v-srcgene of Rous sarcoma virus, has been po lated to play an important role in the development or progressio human colon cancer (Mao et al, 1997).”
BackgroundZhang, Q., Zhou, D., Lei, Y., Li, Z., Chen, S., Gou, H., Gu, Q., He, X., Lan, T., Qi, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3060 · Cited by 41
“Src activation is a multifactorial process involving an interaction between Src and many other receptor tyrosine kinases, such as EGFR, PDGFR, FGFR, CSF-1R, HER2/neu and c-Met [33-39].”
BackgroundA Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer
Delfino, F. J., Stevenson, H. M., & Smithgall, T. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507331200 · Cited by 42
Mechanisms of SOCS3 Phosphorylation upon Interleukin-6 Stimulation
Sommer, U., Schmid, C., Sobota, R. M., Lehmann, U., Stevenson, N. J., Johnston, J. A., Schaper, F., Heinrich, P. C., & Haan, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506008200 · Cited by 50
Qin, B., Ariyama, H., Baba, E., Tanaka, R., Kusaba, H., Harada, M., & Nakano, S. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0219-4 · Cited by 42
“SpeciWcally, c-Src has been found to be highly activated in colon cancer metastasized to the liver [27].”
BackgroundKazansky, A. V., & Rosen, J. M. (2001) · PubMed · Cited by 49
Anbalagan, M., Moroz, K., Ali, A. M., Carrier, L., Glodowski, S., & Rowan, B. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033017 · Cited by 39
“Other studies have shown that cancer cell lines with elevated Src activity are frequently highly metastatic, exhibiting an elevated migration and invasion potential in vitro [31,32,33].”
BackgroundBarraclough, J., Hodgkinson, C. L., Hogg, A., Dive, C., & Welman, A. (2007) · Neoplasia · doi:10.1593/neo.07442 · Cited by 43
Xi, Y., Wei, Y., Sennino, B., Ulsamer, A., Kwan, I., Brumwell, A. N., Tan, K., Aghi, M. K., McDonald, D. M., Jablons, D. M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.530 · Cited by 32
Florio, A. D., Adesso, L., Pedrotti, S., Capurso, G., Pilozzi, E., Corbo, V., Scarpa, A., Geremia, R., Fave, G. D., & Sette, C. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0153 · Cited by 36
Scott, A. J., Song, E., Bagby, S. M., Purkey, A., McCarter, M. D., Gajdos, C., Quackenbush, K. S., Cross, B. R., Pitts, T. M., Tan, A. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187173 · Cited by 40
Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen, T., George, J. A., & Taylor, C. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00002 · Cited by 42
Pecquet, C., Nyga, R., Penard‐Lacronique, V., Smithgall, T. E., Murakami, H., Régnier, A., Lassoued, K., & Gouilleux, F. (2006) · Oncogene · doi:10.1038/sj.onc.1209949 · Cited by 35
“A number of human primary tumours and tumour-derived cell lines including leukaemias possess elevated Src kinase activities (Rosen et al., 1986; Ottenhoff-Kalff et al., 1992; Talamonti et al., 1993; Mao et al., 1997; Donato et al., 2003).”
BackgroundPastor, D. M., Poritz, L. S., Olson, T. L., Kline, C. L. B., Harris, L., Koltun, W. A., Chinchilli, V. M., & Irby, R. (2010) · PubMed · Cited by 52
Self-citationTumor necrosis factor α stimulates invasion of Src-activated intestinal cells
Kawai, N., Tsuji, S., Tsujii, M., Ito, T., Yasumaru, M., Kakiuchi, Y., Kimura, A., Komori, M., Sasaki, Y., Hayashi, N., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31023 · Cited by 35
Bender, C., Henjes, F., Fröhlich, H., Wiemann, S., Korf, U., & Beißbarth, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq385 · Cited by 35
“More hypothetical interactions included the inferred SRC activation (ERBB3 → SRC), interpreted as activation of SRC by ERBB2 (see e.g. Luttrell et al., 1994; Mao et al., 1997; Xian et al., 1997) through the ERBB2/3 heterodimer.”
Background
Metadata
- Authors
- Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- Venue
- Oncogene
- Published
- 1997-12-18
- Volume
- 15
- Issue
- 25
- Pages
- 3083-3090
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2332502334
- Cited by
- 200
- References
- 0
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 6 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 8 · 2016: 2 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 11
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ariad Pharmaceuticals
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- Src kinase, receptor tyrosine kinase, colon cancer, liver metastasis, EGFR, HER2/neu, c-Met, signal transduction, metastatic phenotype, protein kinase activation, EGFR inhibitors, feedback regulation
- MeSH terms
- Colonic Neoplasms, Colonic Polyps, Epidermal Growth Factor, Humans, Neoplasm Metastasis, Neoplasm Proteins, Phenotype, Phosphorylation, Protein Kinases, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Genes, src, Erb-b2 Receptor Tyrosine Kinases, Receptor Protein-Tyrosine Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.